Effect of Antibiotic-Mediated Microbiome Modulation on Rotavirus Vaccine Immunogenicity: A Human, Randomized-Control Proof-of-Concept Trial.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsHarris, Vanessa C
Haak, Bastiaan W
Handley, Scott A
Velasquez, Daniel E
Hykes, Barry L
Berbers, Guy A M
Kemper, Elles Marleen
van Leeuwen, Ester M M
Boele van Hensbroek, Michael
Wiersinga, Willem Joost
MetadataShow full item record
TitleEffect of Antibiotic-Mediated Microbiome Modulation on Rotavirus Vaccine Immunogenicity: A Human, Randomized-Control Proof-of-Concept Trial.
Published inCell Host Microbe 2018; 24(2):197-207.e4
PubliekssamenvattingRotavirus vaccines (RVV) protect against childhood gastroenteritis caused by rotavirus (RV) but have decreased effectiveness in low- and middle-income settings. This proof-of-concept, randomized-controlled, open-label trial tested if microbiome modulation can improve RVV immunogenicity. Healthy adults were randomized and administered broad-spectrum (oral vancomycin, ciprofloxacin, metronidazole), narrow-spectrum (vancomycin), or no antibiotics and then vaccinated with RVV, 21 per group per protocol. Baseline anti-RV IgA was high in all subjects. Although antibiotics did not alter absolute anti-RV IgA titers, RVV immunogenicity was boosted at 7 days in the narrow-spectrum group. Further, antibiotics increased fecal shedding of RV while also rapidly altering gut bacterial beta diversity. Beta diversity associated with RVV immunogenicity boosting at day 7 and specific bacterial taxa that distinguish RVV boosters and RV shedders were identified. Despite the negative primary endpoint, this study demonstrates that microbiota modification alters the immune response to RVV and supports further exploration of microbiome manipulation to improve RVV immunogenicity.
- Significant Correlation Between the Infant Gut Microbiome and Rotavirus Vaccine Response in Rural Ghana.
- Authors: Harris VC, Armah G, Fuentes S, Korpela KE, Parashar U, Victor JC, Tate J, de Weerth C, Giaquinto C, Wiersinga WJ, Lewis KD, de Vos WM
- Issue date: 2017 Jan 1
- Rotavirus vaccine response correlates with the infant gut microbiota composition in Pakistan.
- Authors: Harris V, Ali A, Fuentes S, Korpela K, Kazi M, Tate J, Parashar U, Wiersinga WJ, Giaquinto C, de Weerth C, de Vos WM
- Issue date: 2018 Mar 4
- The fecal microbiome and rotavirus vaccine immunogenicity in rural Zimbabwean infants.
- Authors: Robertson RC, Church JA, Edens TJ, Mutasa K, Min Geum H, Baharmand I, Gill SK, Ntozini R, Chasekwa B, Carr L, Majo FD, Kirkpatrick BD, Lee B, Moulton LH, Humphrey JH, Prendergast AJ, Manges AR, SHINE Trial Team
- Issue date: 2021 Sep 7
- Enteropathogens and Rotavirus Vaccine Immunogenicity in a Cluster Randomized Trial of Improved Water, Sanitation and Hygiene in Rural Zimbabwe.
- Authors: Church JA, Rogawski McQuade ET, Mutasa K, Taniuchi M, Rukobo S, Govha M, Lee B, Carmolli MP, Chasekwa B, Ntozini R, McNeal MM, Moulton LH, Kirkpatrick BD, Liu J, Houpt ER, Humphrey JH, Platts-Mills JA, Prendergast AJ
- Issue date: 2019 Dec
- Predictors of oral rotavirus vaccine immunogenicity in rural Zimbabwean infants.
- Authors: Church JA, Chasekwa B, Rukobo S, Govha M, Lee B, Carmolli MP, Ntozini R, Mutasa K, McNeal MM, Majo FD, Tavengwa NV, Kirkpatrick BD, Moulton LH, Humphrey JH, Prendergast AJ
- Issue date: 2020 Mar 17